Publicaciones en las que colabora con JUAN ALEJANDRO FLORES MONTERO (55)

2023

  1. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

    Blood Cancer Journal

  2. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index

    Blood Cancer Journal, Vol. 13, Núm. 1

  3. Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study

    Blood Cancer Journal, Vol. 13, Núm. 1

  4. Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil

    Cancers, Vol. 15, Núm. 5

2022

  1. Altered innate immune profile in blood of systemic mastocytosis patients

    Clinical and Translational Allergy, Vol. 12, Núm. 6

  2. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161

  3. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  4. Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study

    Blood Advances, Vol. 6, Núm. 3, pp. 976-992

  5. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

    British Journal of Haematology, Vol. 197, Núm. 1, pp. 76-81

  6. Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels

    Cancers, Vol. 14, Núm. 3

  7. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma

    Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871

2021

  1. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

    Modern Pathology, Vol. 34, Núm. 1, pp. 59-69

  2. B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients

    Cancers, Vol. 13, Núm. 7

  3. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  4. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  5. Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma

    Cancers, Vol. 13, Núm. 6, pp. 1-18

  6. Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma

    Cancers, Vol. 13, Núm. 19

2020

  1. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3007-3018

  2. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

  3. Detection of circulating tumor plasma cells in monoclonal gammopathies: Methods, pathogenic role, and clinical implications

    Cancers, Vol. 12, Núm. 6, pp. 1-26